Earnings Labs
Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated (PRLD)

NASDAQ·Healthcare·Biotechnology

$4.29

-5.20%

Mkt Cap $170.52M

Analyst Ratings

No recent rating data.

Price Target (5 analysts)

$6.25

Range $3.00$10.00

Implied Upside

+45.9%

Consensus $6.25 vs current $4.29